Faes Farma Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Faes FarmaDer Gewinn des Unternehmens wird voraussichtlich um 1.4% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 1.5% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich sinken um 1.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 11.2% betragen.
Wichtige Informationen
-1.4%
Wachstumsrate der Gewinne
-1.5%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 26.0% |
| Wachstumsrate der Einnahmen | 1.5% |
| Zukünftige Eigenkapitalrendite | 11.2% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 21 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Faes Farma, S.A. (BME:FAE) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Nov 03
Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year
Jul 31Recent updates
Faes Farma, S.A. (BME:FAE) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Nov 03Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316
Dec 18Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316
Dec 04Does Faes Farma (BME:FAE) Have A Healthy Balance Sheet?
Nov 24Here's Why Faes Farma (BME:FAE) Can Manage Its Debt Responsibly
May 03Is There An Opportunity With Faes Farma, S.A.'s (BME:FAE) 50% Undervaluation?
Sep 21Is Faes Farma (BME:FAE) A Risky Investment?
Aug 03Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth
Jun 17Is Faes Farma (BME:FAE) Using Too Much Debt?
Mar 27Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14
Dec 13Faes Farma's (BME:FAE) Dividend Will Be Increased To €0.17
Nov 29Is Faes Farma (BME:FAE) A Risky Investment?
Sep 21Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year
Jul 31Is Faes Farma (BME:FAE) Using Too Much Debt?
May 01Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)
Apr 07Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?
Mar 22Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak Foundations
Mar 06Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their Investment
Feb 22I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With Ease
Jan 16Faes Farma (BME:FAE) Seems To Use Debt Rather Sparingly
Dec 08Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 509 | 92 | 93 | N/A | 3 |
| 12/31/2025 | 499 | 94 | 82 | N/A | 3 |
| 12/31/2024 | 484 | 90 | 61 | N/A | 3 |
| 9/30/2024 | 504 | 98 | N/A | N/A | N/A |
| 6/30/2024 | 494 | 97 | 44 | 106 | N/A |
| 3/31/2024 | 482 | 95 | N/A | N/A | N/A |
| 12/31/2023 | 473 | 92 | -1 | 101 | N/A |
| 9/30/2023 | 472 | 90 | N/A | N/A | N/A |
| 6/30/2023 | 469 | 90 | -9 | 98 | N/A |
| 3/31/2023 | 467 | 91 | N/A | N/A | N/A |
| 12/31/2022 | 462 | 89 | 26 | 107 | N/A |
| 9/30/2022 | 460 | 86 | N/A | N/A | N/A |
| 6/30/2022 | 466 | 88 | 50 | 113 | N/A |
| 3/31/2022 | 449 | 88 | N/A | N/A | N/A |
| 12/31/2021 | 429 | 82 | 20 | 80 | N/A |
| 9/30/2021 | 416 | 81 | N/A | N/A | N/A |
| 6/30/2021 | 398 | 74 | 8 | 56 | N/A |
| 3/31/2021 | 394 | 73 | N/A | N/A | N/A |
| 12/31/2020 | 411 | 73 | 53 | 78 | N/A |
| 9/30/2020 | 408 | 77 | N/A | N/A | N/A |
| 6/30/2020 | 407 | 73 | 57 | 78 | N/A |
| 3/31/2020 | 409 | 68 | N/A | N/A | N/A |
| 12/31/2019 | 383 | 64 | 46 | 68 | N/A |
| 9/30/2019 | 379 | 60 | N/A | N/A | N/A |
| 6/30/2019 | 363 | 59 | 51 | 74 | N/A |
| 3/31/2019 | 351 | 54 | N/A | N/A | N/A |
| 12/31/2018 | 340 | 52 | 40 | 59 | N/A |
| 9/30/2018 | 334 | 51 | N/A | N/A | N/A |
| 6/30/2018 | 330 | 49 | N/A | 58 | N/A |
| 3/31/2018 | 308 | 47 | N/A | N/A | N/A |
| 12/31/2017 | 282 | 41 | N/A | 42 | N/A |
| 9/30/2017 | 266 | 39 | N/A | N/A | N/A |
| 6/30/2017 | 250 | 39 | N/A | 43 | N/A |
| 3/31/2017 | 241 | 38 | N/A | N/A | N/A |
| 12/31/2016 | 237 | 37 | N/A | 50 | N/A |
| 9/30/2016 | 226 | 35 | N/A | N/A | N/A |
| 6/30/2016 | 222 | 34 | N/A | 40 | N/A |
| 3/31/2016 | 220 | 32 | N/A | N/A | N/A |
| 12/31/2015 | 214 | 30 | N/A | 41 | N/A |
| 9/30/2015 | 207 | 28 | N/A | N/A | N/A |
| 6/30/2015 | 203 | 27 | N/A | 42 | N/A |
| 3/31/2015 | 196 | 26 | N/A | N/A | N/A |
| 12/31/2014 | 198 | 25 | N/A | 32 | N/A |
| 9/30/2014 | 195 | 23 | N/A | N/A | N/A |
| 6/30/2014 | 194 | 24 | N/A | 20 | N/A |
| 3/31/2014 | 192 | 20 | N/A | N/A | N/A |
| 12/31/2013 | 193 | 23 | N/A | 32 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: FAEFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-1.4% pro Jahr).
Ertrag vs. Markt: FAEFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-1.4% pro Jahr).
Hohe Wachstumserträge: FAEFür die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.
Einnahmen vs. Markt: FAEDie Einnahmen des Unternehmens (1.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Spanish (4.9% pro Jahr).
Hohe Wachstumseinnahmen: FAEDie Einnahmen des Unternehmens (1.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: FAEDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (11.2%).